DTE Energy Company 2021 Series E (DTG)vsVertex Pharmaceuticals Inc (VRTX)
DTG
DTE Energy Company 2021 Series E
$17.15
0.00%
NONE · Cap: $26.58B
VRTX
Vertex Pharmaceuticals Inc
$427.38
+0.98%
HEALTHCARE · Cap: $108.71B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
DTG
Avoid23
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DTG.
Margin of Safety
+56.2%
Fair Value
$976.24
Current Price
$427.38
$548.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DTG
DTG has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : DTG
The primary concerns for DTG are Revenue Growth, EPS Growth, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
DTG profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Monitor NONE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (66/100 vs 23/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DTE Energy Company 2021 Series E
NONE · NONE · USA
DTE Energy Company 2021 Series E represents a compelling investment opportunity in the regulated utility sector, emphasizing reliable energy delivery primarily in Michigan. As a subsidiary of DTE Energy, this series highlights a solid financial standing and a dedication to consistent dividend payouts, making it appealing to institutional investors who prioritize stability and lower risk. The company actively promotes sustainability and invests in innovative energy solutions, enhancing its competitive edge while responding to the increasing demand for environmentally friendly practices. Supported by strong infrastructure and a favorable regulatory landscape, DTE Energy is well-positioned to succeed in the evolving energy market.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other NONE Stocks
Want to dig deeper into these stocks?